Lab
Laboratorio Clinico Coamo INC
Laboratorio Clinico Coamo INC was paid $1.58M by Medicaid between Jan 2018 and Dec 2024, across 72 billing codes. Its largest line is 84443, Thyroid stimulating hormone (TSH) — 10% of everything it billed.
33Billing provider infoLABORATORIO CLINICO COAMO INC
COAMO, PR 00769
COAMO, PR 00769
33aNPI1487617841assigned 04/07/2006
33bProvider typeClinical Medical Laboratory
28Total paid$1.58M
24GClaims142,854
24DCodes billed72
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Puerto Rico
Rank by total paid#68 of 777
Median peer was paid$278K
This provider vs. median5.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,696 | $122K | |
| 2019 | 15,647 | $104K | |
| 2020 | 16,859 | $180K | |
| 2021 | 20,337 | $257K | |
| 2022 | 18,401 | $250K | |
| 2023 | 30,605 | $324K | |
| 2024incomplete | 23,309 | $348K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 84443 | Thyroid stimulating hormone (TSH) | 10% | 10,812 | 9,804 | $165K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 9.9% | 4,585 | 3,951 | $157K |
| 80061 | Lipid panel | 8.5% | 10,851 | 9,804 | $134K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 7.2% | 4,810 | 4,123 | $113K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.3% | 14,975 | 13,225 | $101K |
| 36415 | Collection of venous blood by venipuncture | 5.9% | 17,092 | 14,466 | $93K |
| 80053 | Comprehensive metabolic panel | 4.5% | 7,550 | 6,602 | $72K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.0% | 4,828 | 2,140 | $63K |
| 86328 | 3.6% | 3,168 | 1,618 | $57K | |
| 88173 | 3.6% | 211 | 123 | $56K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.3% | 5,982 | 5,389 | $53K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.3% | 2,021 | 1,816 | $52K |
60 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.9% | 917 | $46K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.8% | 6,005 | $44K |
| 81000 | 2.6% | 13,681 | $41K | |
| 84153 | 1.9% | 1,825 | $30K | |
| 86738 | 1.7% | 2,272 | $27K | |
| 82043 | 1.6% | 4,965 | $25K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.5% | 741 | $23K |
| 82274 | 1.4% | 1,661 | $23K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.4% | 703 | $22K |
| 82607 | 1.0% | 1,227 | $16K | |
| 86703 | 1.0% | 1,378 | $16K | |
| 88108 | 1.0% | 139 | $16K | |
| 88172 | <1% | 127 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,725 | $12K |
| 87088 | <1% | 1,521 | $12K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 458 | $11K |
| 84439 | <1% | 1,287 | $10K | |
| 86803 | <1% | 788 | $9K | |
| 85651 | <1% | 2,708 | $9K | |
| 88106 | <1% | 70 | $7K | |
| 85730 | <1% | 1,255 | $6K | |
| 86038 | <1% | 469 | $5K | |
| 84436 | <1% | 775 | $5K | |
| 85610 | <1% | 1,361 | $5K | |
| 86592 | <1% | 1,078 | $4K | |
| 84550 | <1% | 912 | $4K | |
| 82947 | <1% | 897 | $3K | |
| 84460 | <1% | 611 | $3K | |
| 82550 | <1% | 429 | $2K | |
| 84450 | <1% | 575 | $2K | |
| 80050 | General health panel | <1% | 244 | $2K |
| 83970 | <1% | 69 | $2K | |
| 82570 | <1% | 504 | $2K | |
| 83721 | <1% | 208 | $2K | |
| 84478 | <1% | 343 | $2K | |
| 82270 | <1% | 588 | $2K | |
| 82465 | <1% | 328 | $1K | |
| 87581 | <1% | 35 | $1K | |
| 84479 | <1% | 206 | $1K | |
| 87186 | <1% | 55 | $377.01 | |
| 82728 | <1% | 24 | $325.21 | |
| 83655 | <1% | 29 | $305.25 | |
| 84075 | <1% | 72 | $301.22 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 17 | $259.32 |
| 82378 | <1% | 13 | $245.61 | |
| 87077 | <1% | 30 | $204.84 | |
| 87177 | <1% | 27 | $203.07 | |
| 83540 | <1% | 27 | $174.38 | |
| 82951 | <1% | 12 | $147.57 | |
| 84156 | <1% | 48 | $136.25 | |
| 82565 | <1% | 29 | $126.53 | |
| 82952 | <1% | 12 | $119.55 | |
| 84520 | <1% | 28 | $92.26 | |
| 84703 | <1% | 13 | $86.36 | |
| 83690 | <1% | 12 | $70.52 | |
| 82150 | <1% | 12 | $66.20 | |
| 84100 | <1% | 14 | $65.06 | |
| 82950 | <1% | 14 | $63.42 | |
| 87899 | <1% | 171 | $0.02 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 225 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAVILA, KATHERINE (PRESIDENT DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Arecibo Pathology Services CSP | Aibonito, PR | $3.81M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.